Comparison
Hexarelin vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
140703-51-1
2179963-22-7
Molecular weight
887.05 g/mol
4727 g/mol
Half-life
0.9 h
168 h
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
3
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2